![declare timi 58 declare timi 58](https://www.cardiorrenal.es/arxius/imatgesbutlleti/CVOTS_img-8-n.png)
8ĭECLARE is part of the extensive DapaCare clinical programme for Farxiga, which will enrol patients in randomised clinical trials, including a wide range of mechanistic studies, and is supported by a multinational real-world evidence study (CVD-REAL). DECLARE included more than 17,000 patients across 882 sites in 33 countries and was independently run in collaboration with academic investigators from the TIMI study group (Boston, USA) and the Hadassah Hebrew University Medical Center (Jerusalem, Israel).
DECLARE TIMI 58 TRIAL
The results from this landmark trial are especially important since heart failure is an early and frequent complication of diabetes and associated with hospitalisations that result in a considerable societal and economic burden." 1-7ĭr Stephen Wiviott of Brigham and Women's Hospital and Harvard Medical School, a senior investigator with the Thrombolysis in Myocardial Infarction (TIMI) study group and co-principal investigator of the trial, commented: "The DECLARE-TIMI 58 results offer compelling evidence that dapagliflozin helps to address an important medical need among a diverse group of patients with type-2 diabetes by reducing the composite of hospitalisation for heart failure or CV death, with a safety profile supportive of broad use."ĭetailed trial results will be presented on 10 November at the American Heart Association Scientific Sessions 2018 in Chicago, USA.ĭECLARE (Dapagliflozin Effect on Cardiovascular Events)-TIMI 58 is an AstraZeneca-sponsored, randomised, double-blinded, placebo-controlled, multicentre trial designed to evaluate the effect of Farxigacompared with placebo on CV outcomes in adults with T2D at risk of CV events, including patients with multiple CV risk factors or established CV disease. Additionally, fewer MACE events were observed with Farxiga for the other primary efficacy endpoint, however, this did not reach statistical significance.ĭata from DECLARE-TIMI 58 confirmed the well-established safety profile of Farxiga.Įlisabeth Björk, Vice President, Head of Cardiovascular, Renal and Metabolism, Global Medicines Development said: " Farxiga has achieved a statistically-significant and clinically-important reduction in hospitalisation for heart failure or CV death in a broad range of patients with type-2 diabetes and cardiovascular risk. Farxiga achieved a statistically-significant reduction in the composite endpoint of hospitalisation for heart failure (hHF) or CV death, one of the two primary efficacy endpoints. In the DECLARE (Dapagliflozin Effect on Cardiovascular Events)-TIMI 58 trial, Farxiga met its primary safety endpoint of non-inferiority for major adverse cardiovascular events (MACE).
![declare timi 58 declare timi 58](https://1.bp.blogspot.com/-B3MR0NG-ems/XvK356NN4cI/AAAAAAAAXgg/rVSeqqXZ_Vo-2URWOFSHAOLrkIfjcqyugCLcBGAsYHQ/s1600/IMG_20200624_091757.png)
placebo over a period of up to five years, across 33 countries and in more than 17,000 adults with type-2 diabetes (T2D) who have multiple CV risk factors or established CV disease. The trial evaluated the CV outcomes of Farxiga vs. Results confirmed the well-established safety profile of FarxigaĪstraZeneca today announced positive results from the Phase III DECLARE-TIMI 58 cardiovascular (CV) outcomes trial (CVOT) for Farxiga (dapagliflozin), the broadest SGLT2 inhibitor CVOT conducted to date. In hospitalisation for heart failure or CV death in a broad patient population This announcement contains inside informationįarxiga achieved a positive result in the Phase III DECLARE-TIMI 58 trial, a large cardiovascular outcomes trial in 17,000 patients with type-2 diabetesįarxiga met the primary composite endpoint of a statistically-significant reduction